Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manoj Waikar

Psychiatry Los Gatos, CA Medical Doctor

NPI 1821150574 CMS profile 83084

20 E Main St, Los Gatos, CA 95030

Open in the dashboard

General payments

$1,890,800

2,650 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,000 paid to institutions, not to them · program year 2020

Through program year 2025, Manoj Waikar of Los Gatos, CA is reported in the CMS Open Payments database as having received $1,890,800 across 2,650 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $413,164 616
2024 General $299,611 401
2023 General $353,170 439
2022 General $297,020 386
2021 General $182,806 246
2020 General $144,867 216
2019 General $200,161 346

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manoj Waikar
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Manoj Waikar were reported at $413,164. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Manoj Waikar Psychiatry median Middle half National median
2019 $200,161 $184 $59–$605 $163
2020 $144,867 $119 $36–$372 $114
2021 $182,806 $143 $43–$576 $132
2022 $297,020 $153 $50–$590 $149
2023 $353,170 $170 $56–$651 $160
2024 $299,611 $179 $57–$673 $164
2025 $413,164 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $721,504 976 payments
  2. ITI, Inc. $355,603 415 payments
  3. AbbVie, Inc. $286,978 379 payments
  4. Teva Pharmaceuticals USA, Inc. $170,562 179 payments
  5. Axsome Therapeutics, Inc. $104,085 176 payments
  6. Allergan Inc. $83,082 139 payments
  7. Vanda Pharmaceuticals Inc. $74,183 115 payments
  8. Neurocrine Biosciences, Inc. $47,567 106 payments
  9. E.R. Squibb & Sons, L.L.C. $30,791 63 payments
  10. Otsuka America Pharmaceutical, Inc. $8,411 14 payments
  11. Other $8,035 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,389,584 535 payments
  2. Travel and Lodging $320,861 1,143 payments
  3. Consulting Fee $73,368 24 payments
  4. Food and Beverage $54,184 924 payments
  5. Honoraria $52,683 21 payments
  6. Education $119 3 payments
Products named General payments · program years 2019–2025
  1. ARISTADA Cns $426,733 603 payments
  2. ARISTADA Cns $426,733 603 payments
  3. ARISTADA Cns $426,503 593 payments
  4. ARISTADA Cns $426,503 593 payments
  5. ARISTADA INITIO $413,616 571 payments
  6. LYBALVI Cns $302,018 412 payments
  7. LYBALVI Cns $288,901 380 payments
  8. LYBALVI Cns $288,671 370 payments
  9. LYBALVI Cns $288,671 370 payments
  10. CAPLYTA $277,675 296 payments
  11. Other $887,740 1,374 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

115

Median for Psychiatry & Neurology: 100

Drug cost

$28,657

Median for Psychiatry & Neurology: $2,986

Branded share of claims

42.6%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 13 $18,359
Trintellix Vortioxetine Hydrobromide Brand 12 $5,500
Dayvigo Lemborexant Brand 12 $3,791
Ziprasidone Hcl Generic 26 $650
Bupropion Hcl Sr Bupropion Hcl Brand 12 $201
Trazodone Hcl Generic 14 $76
Duloxetine Hcl Generic 13 $60
Buspirone Hcl Generic 13 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$83,240 13 —
LYBALVI
$63,352 — —
CAPLYTA
$59,248 — —
Auvelity
$26,704 — —
FANAPT
$22,261 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

2,650 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record